Statistics from Altmetric.com
Randomised trials have shown that patients with atrial fibrillation (AF) who are treated with a non-vitamin K antagonist oral anticoagulant (NOAC), compared with warfarin, have similar or lower rates of stroke and major bleeding, markedly reduced rates of intracranial bleeding and a consistent pattern of reduced mortality.1 Dabigatran 150 mg two times a day is the only NOAC that can significantly reduce ischaemic stroke compared with warfarin and can produce even greater ischaemic stroke reduction in patients with prior stroke.2 European guidelines endorse the preferential …
Competing interests JWE has received honoraria from Bayer, BI, BMS, Daiichi-Sankyo, Janssen and Pfizer. JB has received honoraria from BMS and Pfizer.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.